In Brief: Vagistat-1
This article was originally published in The Tan Sheet
Executive Summary
Vagistat-1: Bristol-Myers Squibb's one-dose vaginal yeast infection treatment generates sales of $16 mil. in food, drug and mass merchandise outlets from its mid-April launch to Sept. 14, according to Chicago-based Information Resources, Inc. The brand recorded $10 mil. in sales its first two months on the market ("The Tan Sheet" July 28, p. 7). The top brand, J&J's Monistat 3, had sales of $64.4 mil. in the 52 weeks ended Sept. 14, followed by Monistat 7 ($55.5 mil.), Bayer's Femstat 3 ($44.8 mil.) and Schering-Plough's Gyne-Lotrimin 3 ($20.3 mil.), according to IRI. Vagistat-1 sales have surpassed sales for regular strength Gyne-Lotrimin ($13.6 mil.) and Bayer's value-priced Mycelex-7 ($12.6 mil.) and Mycelex-3 ($7.1 mil.)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning